E
Alpha Cognition Inc. ACOGD
OTC PK
Recommendation
Sell
Prev Close
$5.70
Volume
--
Avg Vol (90D)
10,135
Market Cap
$34.68M
Dividend & Yield
--
52-Week Range
$5.61 - $18.50
P/E (TTM)
--
EPS (TTM)
-$3.42
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Weak
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
4/1/2025 - Newsfile Corp. - News Releases
Alpha Cognition (NASDAQ:ACOG) Announces Earnings Results, Misses Estimates By $0.03 EPS
4/1/2025 - Ticker Report
Alpha Cognition's (ACOG) "Buy" Rating Reaffirmed at HC Wainwright
4/1/2025 - MarketBeat
Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript
4/1/2025 - SeekingAlpha
Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript
4/1/2025 - Seeking Alpha: Transcripts
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
3/31/2025 - Business Wire
Raymond James Upgrades Alpha Cognition (NASDAQ:ACOG) to Moderate Buy
3/27/2025 - Ticker Report
Alpha Cognition (ACOG) Projected to Release Quarterly Earnings on Wednesday
3/26/2025 - MarketBeat
Rosalind Advisors Inc. Invests $1.49 Million in Alpha Cognition, Inc. (NASDAQ:ACOG)
3/23/2025 - MarketBeat
HC Wainwright Weighs in on Alpha Cognition Q1 Earnings
3/21/2025 - MarketBeat
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
3/19/2025 - GuruFocus
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
3/19/2025 - Business Wire
HC Wainwright Initiates Coverage on Alpha Cognition (NASDAQ:ACOG)
3/19/2025 - MarketBeat
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
3/18/2025 - Benzinga
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment ...
3/18/2025 - GuruFocus
Alpha Cognition commercially launches ZUNVEYL to treat mild to moderate AD
3/18/2025 - The Fly
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimers Disease
3/18/2025 - Business Wire
Alpha Cognition initiated with bullish view at H.C. Wainwright, here's why
3/18/2025 - The Fly
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
3/5/2025 - Insider Monkey
Institutions profited after Alpha Cognition Inc.'s (NASDAQ:ACOG) market cap rose US$12m last week but retail investors profited the most
2/20/2025 - Simply Wall St
Ikarian Capital, LLC Acquires Significant Stake in Alpha Cognition Inc
2/14/2025 - GuruFocus
Solas Capital Management, LLC Acquires Significant Stake in Alpha Cognition Inc
2/14/2025 - GuruFocus
AWM Investment Company, Inc. Acquires Significant Stake in Alpha Cognition Inc.
2/14/2025 - GuruFocus
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment ...
2/12/2025 - GuruFocus
Alpha Cognition secures additional patent for Zunveyl from USPTO
2/12/2025 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$11.88M
EBIT (TTM)
-$11.96M
Net Income (TTM)
-$16.23M
Balance Sheet
Total Assets (Q)
$2.08M
Total Debt (Q)
$1.21M
Total Liabilities (Q)
$3.48M
Book Value Per Share (Q)
-$0.2315
Cash Flow
Cash from Operations (TTM)
-$7.55M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$7.53M
Net Change in Cash (TTM)
-$23.60K
Filings
Filing Date
Monday, August 12, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Nov 25 and 29 (est)
Price History
Loading...
Beta
-0.51
7-Day Total Return
-34.86%
30-Day Total Return
-41.61%
60-Day Total Return
-54.85%
90-Day Total Return
-59.60%
Year to Date Total Return
-54.40%
1-Year Total Return
-4.04%
2-Year Total Return
-41.44%
3-Year Total Return
-74.63%
5-Year Total Return
--
52-week Low
Nov 12, 2024 - $5.61
52-week High
Jan 19, 2024 - $18.50
Valuation
Market Cap
$34.68M - Nano Cap
Enterprise Value
$34.87M
Price/Sales (TTM)
--
Price/Book (Q)
-24.62
Dividends and Shares
Shares Outstanding
6.01M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.alphacognition.com
Phone Number
604-564-9244
Address
750 West Pender Street
Vancouver, BC V6C 2T8
Country
Canada
Year Founded
2000
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of... more
Weiss Ratings